title: Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer.
abstract: OBJECTIVE
  We previously identified three clinical predictive factors of efficacy of cetuximab-irinotecan. Here, we analyzed the clinical characteristics of patients with metastatic colorectal cancer (CRC) in order to detect potent correlations with KRAS mutations.
  
  
  METHODS
  We conducted a retrospective, multicenter study between 2008 and 2012. We included patients with metastatic colorectal adenocarcinomas, previously treated by irinotecan, and with an available KRAS mutation test.
  
  
  RESULTS
  We included 299 patients. The median age was 60 years; the median number of metastatic sites was 2. One hundred and eight patients (36.1%) had a previous objective response to irinotecan. The median interval between diagnosis and irinotecan discontinuation was 1.94 years. A KRAS mutation was detected in 133 patients (44.5%). In univariate and multivariate analyses, none of the assessed factors was associated with the presence of a KRAS mutation.
  
  
  CONCLUSIONS
  No easily clinically assessable parameter was significantly associated with KRAS mutations in patients with colorectal cancer.
authors.affiliation: Department of Medical Oncology, University Hospital, Lille, France anne.ploquin@chru-lille.fr.
authors.forename: Anne
authors.initials: A
authors.lastname: Ploquin
authors.affiliation: Biomolecular platform, University Hospital, Lille, France.
authors.forename: Farid
authors.initials: F
authors.lastname: Zerimech
authors.affiliation: Biomolecular platform, University Hospital, Lille, France.
authors.forename: Fabienne
authors.initials: F
authors.lastname: Escande
authors.affiliation: Department of Urodigestive Oncology, Oscar Lambret Center, Lille, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Adenis
authors.affiliation: Department of Oncology, Leonard de Vinci Hospital, Douai, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Giraud
authors.affiliation: Department of Oncology, Joliot Curie Center, Boulogne-sur-mer, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Gasnault
authors.affiliation: Department of Medical Oncology, University Hospital, Lille, France Department of Oncology, General Hospital, Boulogne-sur-mer, France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Bourgeois
authors.affiliation: Department of Medical Oncology, University Hospital, Lille, France Department of Oncology, General Hospital, Calais, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Desauw
authors.affiliation: Department of Medical Oncology, University Hospital, Lille, France.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Hebbar
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000401:mortality / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D004252:DNA Mutational Analysis; D018572:Disease-Free Survival; D005260:Female; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D012189:Retrospective Studies
chemical_list: C117307:KRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)
keywords: Predictive factor; cetuximab; delay of introduction; irinotecan; number of metastatic sites